Miller Fisher Syndrome Following Vaccination against SARS-CoV-2 |
| |
| Authors: | Makoto Yamakawa Keiichi Nakahara Toshihito Nakanishi Toshiya Nomura Mitsuharu Ueda |
| |
| Affiliation: | 1.Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan; 2.Department of Neurology, Kumamoto Kinoh Hospital, Japan |
| |
| Abstract: | ![]()
After BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination, a 30-year-old man developed bilateral lateral gaze palsy, diplopia, absent tendon reflexes, and ataxic gait. Serum anti-GQ1b and anti-GT1a immunoglobulin G (IgG) antibodies were strongly positive. Based on those findings, he was diagnosed with Miller Fisher syndrome (MFS). Intravenous immunoglobulin therapy was administered, and his symptoms fully recovered within approximately 3 months. To the best of our knowledge, this is the first report to describe the development of MFS after COVID-19 mRNA vaccination. |
| |
| Keywords: | Miller Fisher syndrome vaccine COVID-19 SARS-CoV-2 adverse event |
|
|
